Skip to content
naulon
Not checkedNot checked for notices yet.

Current knowledge on mechanisms involved in SARS-CoV-2 infection and kidney diseases

MD. Hasanur Rahman, Md. Sarwar Zahan, Tasnin Al Hasib and 5 more

Journal of Advanced Biotechnology and Experimental Therapeutics

doi:10.5455/jabet.2020.d153 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a global pandemic, spreading rapidly and destroying global health and economy. SARS-CoV-2 infected patients are hospitalized with pneumonia where almost 20-30% of patients are led to kidney failure. The entry of SARS-CoV-2 into the systemic circulation leads to acute kidney injury (AKI) which may develop chronic kidney disease (CKD). In addition, patients who are diagnosed with AKI or CKD are at major risk of SARS-CoV-2 infection. Although a significant number of compounds have been proposed and the existing drugs have also been tested for repurposing, no specific therapy has been approved yet. SARS-CoV-2 invades human cells binding to the receptor of angiotensin-converting enzyme II (ACE2) via the receptor-binding domain. Cells that express ACE2 are susceptible to SARS-CoV-2 infection and the proportion of ACE2-positive cells in kidney proximal tubule is approximately 4%, indicating that SARS-CoV-2 might damage the kidney tubules leading to fatal kidney injury. Therefore, a better understanding of the potential mechanisms involved in SARS-CoV-2 infection-mediated kidney disease may unveil a novel therapeutic strategy against kidney diseases during COVID-19. [ J Adv Biotechnol Exp Ther 2020; 3(4.000): 30-35]

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.